시장보고서
상품코드
1150082

세계의 겸상 적혈구증 치료 시장 점유율, 규모, 동향, 산업 분석 리포트 : 치료법별, 최종사용자별, 지역별, 부문 예측(2022-2030년)

Sickle Cell Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant); By End-Use; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 122 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 겸상 적혈구증 치료 시장 규모는 2030년까지 69억 4,000만 달러에 달할 것으로 예측되고 있습니다.

세계의 겸상 적혈구증 치료 시장에 대해 조사분석했으며, 시장 역학, 부문 분석, 지역 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 리포트 설명
    • 조사 목적
    • 시장 범위
    • 전제조건
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 데이터 소스
    • 1차 소스
    • 2차 소스

제4장 세계의 겸상 적혈구증 치료 시장 인사이트

  • 겸상 적혈구증 치료 시장 : 업계의 스냅숏
  • 겸상 적혈구증 치료 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter's Five Forces 분석
    • 공급 기업의 교섭력(중)
    • 신규 참여업체의 위협(저)
    • 구매자의 교섭력(중)
    • 대체품의 위협(중)
    • 기존 기업간 경쟁력(고)
  • PESTLE 분석
  • 겸상 적혈구증 치료 업계의 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 겸상 적혈구증 치료 시장 : 치료법별

  • 주요 조사 결과
  • 서론
    • 치료법별 : 2018-2030년
  • 수혈
    • 수혈별, 지역별 : 2018-2030년
  • 약물 요법
    • 약물 요법별, 지역별 : 2018-2030년
    • 히드록시우레아
    • 브랜드 의약품
  • 골수 이식
    • 골수 이식별, 지역별 : 2018-2030년

제6장 세계의 겸상 적혈구증 치료 시장 : 최종사용자별

  • 주요 조사 결과
  • 서론
    • 최종사용자별 : 2018-2030년
  • 병원
    • 병원별, 지역별 : 2018-2030년
  • 전문 클리닉
    • 전문 클리닉별, 지역별 : 2018-2030년
  • 기타
    • 기타별, 지역별 : 2018-2030년

제7장 세계의 겸상 적혈구증 치료 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 겸상 적혈구증 치료 시장 평가 - 지역별 : 2018-2030년
  • 북미
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 미국
    • 캐나다
  • 유럽
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 아시아태평양
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
  • 중동·아프리카
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
  • 라틴아메리카
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 멕시코
    • 브라질
    • 아르헨티나

제8장 경쟁 구도

  • 사업 확장과 인수 분석
    • 사업 확장
    • 인수
  • 제휴/협업/협정/전시회

제9장 기업 개요

  • AstraZeneca Plc.
  • Acceleron Pharma, Inc.
  • Arena Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Bluebird bio, Inc.
  • Emmaus Life Sciences, Inc.
  • Eli Lilly and Company
  • Global Blood Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
KSA 22.11.18

The global sickle cell disease treatment market size is expected to reach USD 6.94 billion by 2030, according to a new study by Polaris Market Research. The report "Sickle Cell Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant); By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The significant number of unmet medical needs, a healthy pipeline, and a growing patient pool are all expected to boost market growth. As a result of the lack of a complete cure and the risks associated with bone marrow transplantation, there has been an increase in demand for cost-effective drugs and gene therapy for sickle cell disease (SCD) in recent years.

Gene therapy has appeared as the ultimate solution for several critical ailments. In the case of genetic disorders, gene therapy represents a revolution that addresses the disease's underlying cause. Companies are moving their R&D attention to genetic therapy to fix the genetic mutation in SCD.

Moreover, in May 2020, CRISPER Therapeutics and Vertex Pharmaceuticals are also undertaking clinical studies for CTX001, a CRISPR-Cas9 gene-edited treatment. They confirmed that the FDA had granted CTX001, an interventional, patient-derived, gene-edited stem cell-derived hematopoietic therapy, Regenerative Medicine Advanced Therapy (RMAT) distinction for the treatment of serious sickle cell disorder, and transfusion-dependent beta-thalassemia (TDT).

Positive clinical tests on CTX001 indicate that the pipeline candidate has the potential to become a blockbuster medicine when it is released. This is projected to drive significant expansion in the SCD therapy industry. Furthermore, the government is funding research and development (R&D) operations designed to motivate researchers and pharmaceutical businesses to create novel medicines.

Sickle Cell Disease Treatment Market Report Highlights

Bone Marrow Transplant (BMT) segment is anticipated to grow at a significant CAGR over the forecast period. Only bone marrow transplantation (BMT) can cure SCD. As a result, the preference for BMT is growing throughout North America and Europe. However, the procedure's high cost and difficulties in locating a matched donor restrict the segment's growth.

Pharmacotherapy segment accounted for a significant revenue share. The government's significant support for pharmaceutical businesses can be ascribed to the segment's rapid expansion. Because there are currently few therapy choices on the market, the government encourages research through financing and classifications like orphan pharmaceuticals, fast track, issues that will affect, and others.

Asia Pacific is expected to grow at a lucrative CAGR over the projected period. Because of a rising patient population and increasing disposable income levels in this region. Furthermore, the expansion of the healthcare system and increasing government efforts would accelerate the market's growth in this region.

The global players with a global presence include AstraZeneca, Acceleron Pharma, Inc., Arena Pharmaceuticals, Emmaus Life Sciences, Blood Therapeutics, Novartis, Pfizer Incorporation, and Sangamo Therapeutics.

Polaris Market Research has segmented the sickle cell disease treatment market report based on treatment, end-use, and region:

Sickle Cell Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2018 - 2030)

Blood Transfusion

Pharmacotherapy

Hydroxyurea

Branded Drugs

Endari

Adakveo

Oxbryta

Zynteglo

CTX001

Mitapivat

FT-4202

Bone Marrow Transplant

Sickle Cell Disease Treatment, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Specialty Clinics

Others

Sickle Cell Disease Treatment, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Sickle Cell Disease Treatment Market Insights

  • 4.1. Sickle Cell Disease Treatment Market - Industry Snapshot
  • 4.2. Sickle Cell Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High unmet needs
      • 4.2.1.2. Increasing prevalence of hemoglobinopathies in under-developed countries
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of healthcare infrastructure
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Sickle Cell Disease Treatment Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Sickle Cell Disease Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Sickle Cell Disease Treatment, by Treatment, 2018 - 2030 (USD Billion)
  • 5.3. Blood Transfusion
    • 5.3.1. Global Sickle Cell Disease Treatment Market, by Blood Transfusion, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Pharmacotherapy
    • 5.4.1. Global Sickle Cell Disease Treatment Market, by Pharmacotherapy, by Region, 2018 - 2030 (USD Billion)
    • 5.4.2. Hydroxyurea
      • 5.4.2.1. Global Sickle Cell Disease Treatment Market, by Hydroxyurea, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3. Branded Drugs
      • 5.4.3.1. Global Sickle Cell Disease Treatment Market, by Branded Drugs, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.2. Endari
      • 5.4.3.2.1. Global Sickle Cell Disease Treatment Market, by Endari, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.3. Adakveo
      • 5.4.3.3.1. Global Sickle Cell Disease Treatment Market, by Adakveo, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.4. Oxbryta
      • 5.4.3.4.1. Global Sickle Cell Disease Treatment Market, by Oxbryta, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.5. Zynteglo
      • 5.4.3.5.1. Global Sickle Cell Disease Treatment Market, by Zynteglo, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.6. CTX001
      • 5.4.3.6.1. Global Sickle Cell Disease Treatment Market, by CTX001, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.7. Mitapivat
      • 5.4.3.7.1. Global Sickle Cell Disease Treatment Market, by Mitapivat, by Region, 2018 - 2030 (USD Billion)
      • 5.4.3.8. FT-4202
      • 5.4.3.8.1. Global Sickle Cell Disease Treatment Market, by FT-4202, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Bone Marrow Transplant
    • 5.5.1. Global Sickle Cell Disease Treatment Market, by Bone Marrow Transplant, by Region, 2018 - 2030 (USD Billion)

6. Global Sickle Cell Disease Treatment Market, by End-Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Sickle Cell Disease Treatment Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Specialty Clinics
    • 6.4.1. Global Sickle Cell Disease Treatment Market, by Specialty Clinics, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Sickle Cell Disease Treatment Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Sickle Cell Disease Treatment Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Sickle Cell Disease Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Sickle Cell Disease Treatment Market - North America
    • 7.3.1. North America: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.3.3. Sickle Cell Disease Treatment Market - U.S.
      • 7.3.3.1. U.S.: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.3.4. Sickle Cell Disease Treatment Market - Canada
      • 7.3.4.1. Canada: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4. Sickle Cell Disease Treatment Market - Europe
    • 7.4.1. Europe: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.3. Sickle Cell Disease Treatment Market - UK
      • 7.4.3.1. UK: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.4. Sickle Cell Disease Treatment Market - France
      • 7.4.4.1. France: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.5. Sickle Cell Disease Treatment Market - Germany
      • 7.4.5.1. Germany: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.6. Sickle Cell Disease Treatment Market - Italy
      • 7.4.6.1. Italy: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.7. Sickle Cell Disease Treatment Market - Spain
      • 7.4.7.1. Spain: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.8. Sickle Cell Disease Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.4.9. Sickle Cell Disease Treatment Market - Russia
      • 7.4.9.1. Russia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5. Sickle Cell Disease Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.3. Sickle Cell Disease Treatment Market - China
      • 7.5.3.1. China: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.4. Sickle Cell Disease Treatment Market - India
      • 7.5.4.1. India: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.5. Sickle Cell Disease Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.6. Sickle Cell Disease Treatment Market - Japan
      • 7.5.6.1. Japan: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.7. Sickle Cell Disease Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.5.8. Sickle Cell Disease Treatment Market - South Korea
      • 7.5.8.1. South Korea: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.6. Sickle Cell Disease Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.6.3. Sickle Cell Disease Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.6.4. Sickle Cell Disease Treatment Market - UAE
      • 7.6.4.1. UAE: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.6.5. Sickle Cell Disease Treatment Market - Israel
      • 7.6.5.1. Israel: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.6.6. Sickle Cell Disease Treatment Market - South Africa
      • 7.6.6.1. South Africa: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.7. Sickle Cell Disease Treatment Market - Latin America
    • 7.7.1. Latin America: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.7.3. Sickle Cell Disease Treatment Market - Mexico
      • 7.7.3.1. Mexico: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.7.4. Sickle Cell Disease Treatment Market - Brazil
      • 7.7.4.1. Brazil: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 7.7.5. Sickle Cell Disease Treatment Market - Argentina
      • 7.7.5.1. Argentina: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca Plc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Acceleron Pharma, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Arena Pharmaceuticals, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Alnylam Pharmaceuticals, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Baxter International Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Bristol-Myers Squibb Company
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Bluebird bio, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Emmaus Life Sciences, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Eli Lilly and Company
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Global Blood Therapeutics Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Novartis AG
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Pfizer Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Sangamo Therapeutics, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제